Othman Al-Sawaf

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9576377/publications.pdf

Version: 2024-02-01

67 papers	2,278 citations	394421 19 h-index	223800 46 g-index
71 all docs	71 docs citations	71 times ranked	2737 citing authors

#	Article	IF	Citations
1	Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. New England Journal of Medicine, 2019, 380, 2225-2236.	27.0	599
2	Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2020, 21, 1188-1200.	10.7	208
3	Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2021, 9, 522-532.	10.7	195
4	Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. American Journal of Hematology, 2021, 96, 1679-1705.	4.1	150
5	Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood, 2017, 129, 2702-2705.	1.4	108
6	Nrf2Âin health and disease: current and future clinical implications. Clinical Science, 2015, 129, 989-999.	4.3	101
7	Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2018, 19, 1215-1228.	10.7	94
8	Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Blood, 2020, 135, 2402-2412.	1.4	83
9	Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. Journal of Clinical Oncology, 2021, 39, 4049-4060.	1.6	74
10	Richter transformation in chronic lymphocytic leukemia (CLL)â€"a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials. Leukemia, 2021, 35, 169-176.	7.2	55
11	Nrf2 augments skeletal muscle regeneration after ischaemiaâ€"reperfusion injury. Journal of Pathology, 2014, 234, 538-547.	4.5	48
12	Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology,the, 2017, 4, e475-e486.	4.6	45
13	The CLL12 trial: ibrutinib vs placebo in treatment-naÃ¯ve, early-stage chronic lymphocytic leukemia. Blood, 2022, 139, 177-187.	1.4	40
14	CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. Leukemia, 2019, 33, 1161-1172.	7.2	38
15	Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. Leukemia, 2020, 34, 2038-2050.	7.2	38
16	Using DNA sequencing data to quantify T cell fraction and therapy response. Nature, 2021, 597, 555-560.	27.8	36
17	High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia. Blood, 2020, 135, 866-870.	1.4	30
18	IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENTâ€NAÃVE EARLY STAGE CLL: PRIMARY ENDPOINT RESULTS OF THE PHASE 3 DOUBLEâ€BLIND RANDOMIZED CLL12 TRIAL. Hematological Oncology, 2019, 37, 38-40.	1.7	28

#	Article	IF	Citations
19	Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia. Hematology American Society of Hematology Education Program, 2020, 2020, 357-362.	2.5	22
20	Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial. Blood, 2020, 136, 22-23.	1.4	20
21	Nrf2 Protects Against TWEAK-mediated Skeletal Muscle Wasting. Scientific Reports, 2014, 4, 3625.	3.3	19
22	Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial. Blood, 2019, 134, 36-36.	1.4	18
23	Current Perspectives on Therapy for Chronic Lymphocytic Leukemia. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 320-329.	3.8	16
24	Durable Remissions after Discontinuation of Combined Targeted Treatment in Patients with Chronic Lymphocytic Leukemia (CLL) Harbouring a High-Risk Genetic Lesion (del(17p)/TP53 Mutation). Blood, 2018, 132, 694-694.	1.4	16
25	Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy. Drug Design, Development and Therapy, 2017, Volume11, 295-304.	4.3	15
26	A Novel Laser-Doppler Flowmetry Assisted Murine Model of Acute Hindlimb Ischemia-Reperfusion for Free Flap Research. PLoS ONE, 2013, 8, e66498.	2.5	13
27	Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicentre, open-label phase-II trial. Haematologica, 2021, 106, 543-554.	3.5	12
28	Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group). Blood, 2016, 128, 229-229.	1.4	12
29	Targeted Therapy of CLL. Oncology Research and Treatment, 2016, 39, 768-778.	1.2	9
30	Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review. Therapeutic Advances in Hematology, 2017, 8, 197-205.	2.5	9
31	Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial. European Journal of Haematology, 2017, 98, 254-262.	2.2	9
32	Management of an adult patient with sickle cell disease and acute chest syndrome by veno-venous extracorporeal membrane oxygenation. Annals of Hematology, 2019, 98, 789-791.	1.8	9
33	Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?. Hematology/Oncology Clinics of North America, 2021, 35, 775-791.	2.2	8
34	Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323). Blood, 2016, 128, 2054-2054.	1.4	8
35	Outcome of patients aged 80Âyears or older treated for chronic lymphocytic leukaemia. British Journal of Haematology, 2018, 183, 727-735.	2.5	7
36	Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations. Blood, 2021, 138, 1805-1816.	1.4	7

#	Article	IF	Citations
37	BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G) AND VENETOCLAX (A) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2â€BAG TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG). Hematological Oncology, 2017, 35, 25-27.	1.7	6
38	Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group. Leukemia, 2017, 31, 2251-2253.	7.2	6
39	Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia. Haematologica, 2019, 104, e224-e226.	3.5	6
40	Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy. Leukemia, 2020, 34, 1177-1181.	7.2	6
41	Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL). American Journal of Hematology, 2019, 94, 1002-1006.	4.1	5
42	Healthâ€related quality of life with fixedâ€duration venetoclaxâ€obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 <scp>CLL14</scp> trial. American Journal of Hematology, 2021, 96, 1112-1119.	4.1	5
43	Low Incidence of Tumor Lysis Syndromes (TLS) and Infusion Related Reactions (IRR) in the CLL2-Bag Trial Evaluating a Sequential Treatment of Bendamustine (B), Obinutuzumab (GA101, G) and Venetoclax (ABT-199, A) in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Safety Results of a Phase-II-Trial of the German CLL Study Group (GCLLSG). Blood, 2016, 128, 2044-2044.	1.4	4
44	Fixed-duration venetoclax-obinutuzumab for previously untreated patients with chronic lymphocytic leukemia: Follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial.. Journal of Clinical Oncology, 2020, 38, 8027-8027.	1.6	4
45	ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia. Blood, 2021, 138, 2634-2634.	1.4	4
46	Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial. Leukemia, 2022, 36, 2125-2128.	7.2	4
47	GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORABMUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY Best abstract submitted by a young investigator / travel grant recipient. Hematological Oncology, 2019, 37, 84-86.	1.7	3
48	Prevention and Management of Tumor Lysis Syndrome in Patients with CLL and Coexisting Conditions Treated with Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Results from the Randomized CLL14 Trial. Blood, 2019, 134, 4315-4315.	1.4	3
49	Bendamustine Followed By Obinutuzumab and Idelalisib in Patients with Chronic Lymphocytic Leukemia (CLL): CLL2-BCG Trial of the German CLL Study Group (GCLLSG). Blood, 2020, 136, 21-23.	1.4	3
50	Pelvic cellulitis caused by Raoultella planticola in a neutropenic patient. Journal of Infection and Chemotherapy, 2019, 25, 298-301.	1.7	2
51	Rapid Improvement of Patient-Reported Outcomes with Venetoclax Plus Obinutuzumab in Patients with Previously Untreated CLL and Coexisting Conditions: A Prospective Analysis from the CLL14 Trial. Blood, 2019, 134, 4305-4305.	1.4	2
52	Severe Infections in Patients with Chronic Lymphocytic Leukemia Treated with (Immuno-)Chemotherapy: A Pooled Analysis of Gcllsg Trials. Blood, 2020, 136, 18-19.	1.4	2
53	Initial Therapy of Chronic Lymphocytic Leukemia. Hematologic Malignancies, 2019, , 79-96.	0.2	2
54	Sequential Treatment with Bendamustine, Obinutuzumab (GA101) and Ibrutinib in Chronic Lymphocytic Leukemia (CLL): Final Results of the CLL2-BIG Trial of the German CLL Study Group (GCLLSG). Blood, 2019, 134, 3046-3046.	1.4	2

#	Article	IF	Citations
55	TP53mutations in CLL: does frequency matter?. Blood, 2021, 138, 2600-2601.	1.4	2
56	HIGH EFFICACY OF VENETOCLAX PLUS OBINUTUZUMAB IN PATIENTS WITH COMPLEX KARYOTYPE (CKT) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PROSPECTIVE ANALYSIS FROM THE CLL14 TRIAL. Hematological Oncology, 2019, 37, 104-106.	1.7	1
57	Impact of Gender on Outcome after Chemoimmunotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) or Bendamustine Plus Rituximab (BR) in Patients with Chronic Lymphocytic Leukemia (CLL): A Meta-Analysis of Three Phase II/III Studies of the German CLL Study Group (GCLLSG). Blood, 2016, 128, 4394-4394.	1.4	1
58	Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRDâ€“) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and comorbidities.. Journal of Clinical Oncology, 2019, 37, 7502-7502.	1.6	1
59	Pooled Analysis of First-Line Treatment with Targeted Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Aged 80 Years and Older. Blood, 2021, 138, 1552-1552.	1.4	1
60	CHARACTERISTICS, TREATMENT, AND OUTCOMES OFÂâ‰¥Â80 YEAR OLD PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ENROLLED TO PROSPECTIVE TRIALS OF THE GERMAN CLL STUDY GROUP. Hematological Oncology, 2017, 35, 99-100.	1.7	0
61	FIXED-DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES. Hematological Oncology, 2019, 37, 82-84.	1.7	0
62	Progression By Lymphocytosis Correlates with Favourable Long-Term Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL). Blood, 2016, 128, 4352-4352.	1.4	0
63	Comparison of different phase II studies using sequential combinations of targeted agents for treating chronic lymphocytic leukemia.. Journal of Clinical Oncology, 2018, 36, 7513-7513.	1.6	0
64	Obesity Negatively Impacts Outcome in Female Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR): An Analysis of Three Phase III Studies of the German CLL Study Group (GCLLSG). Blood, 2018, 132, 4429-4429.	1.4	0
65	Acalabrutinib monotherapy in patients with Richter transformation. Lancet Haematology,the, 2021, 8, e868-e870.	4.6	0
66	The role of minimal residual disease in chronic lymphocytic leukemia.. Clinical Advances in Hematology and Oncology, 2022, 20, 97-103.	0.3	0
67	Pharmacokinetics and Exposure-Response Analysis of Venetoclaxâ€‰+â€‰Obinutuzumab in Chronic Lymphocytic Leukemia: PhaseÂ1b Study and PhaseÂ3 CLL14 Trial. Advances in Therapy, 0, , .	2.9	0